Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the use of novel approaches to deliver these new medicines to patients. Our CEO, Mihael Polymeropoulos, MD, founded Vanda in 2003 in partnership with Care Capital LLC, a prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises.
President and Chief Executive Officer
Executive Vice President,
Chief Financial Officer and
Treasurer
Senior Vice President,
Business Development
Senior Vice President,
General Counsel and Secretary
Senior Vice President,
Chief Commercial Officer
Vice President of Manufacturing
Chief of Corporate Affairs and Communications Officer
Senior Vice President, Chief Marketing Officer
Chief People Officer
Michael F. Cola
Member
Richard W. Dugan (Financial Expert)
Chair, Member
Phaedra Chrousos
Member
Michael F. Cola
Chair, Member
H. Thomas Watkins
Member
Richard W. Dugan
Member
Richard W. Dugan
Member
H. Thomas Watkins
Chair, Member
Vanda Pharmaceuticals Inc. Corporate Governance Guidelines
PDF 27.0 KB
Vanda Germany - 2018 Payments to Patient Organizations
PDF 285.0 KB
Audit Committee
PDF 46.0 KB
Compensation Committee
PDF 33.0 KB
Nominating and Corporate Governance Committee
PDF 17.0 KB
Whistleblower Policy
PDF 100.0 KB
Code of Business Conduct and Ethics
PDF 118.0 KB
Securities Trading
PDF 125.0 KB
Reg FD Policy
PDF 64.0 KB
Amended and Restated Bylaws
PDF 138.0 KB
Amended and Restated Certificate of Incorporation
PDF 86.0 KB
Certificate of Designation
PDF 164.0 KB
Comprehensive Compliance Program
PDF 17.0 KB
Annual CA Declaration of Compliance
PDF 135.0 KB